NEWS AND VIEWS FROM THE PHARMACEUTICAL FINE CHEMICAL AND CUSTOM MANUFACTURING SECTOR

Thursday 24 January 2013

Challenging year for Lonza custom manufacturing

Following it acquisition of Arch in 2012, Lonza has reported full year sales of CHF3.93bn. The company reported that sales in custom manufacturing rose 1.5% to CHF1.3bn but Lonza CEO Richard Ridinger said he was unsatisfied with the EBIT performance for the division. The company said it has more than 350 products in its chemical manufacturing pipeline and utilisation was above 75%, close to the 78% reported for 2011. For biologics the company has 340 active projects and capacity utilisation above 70%, down from 87% last year before the Singapore facility opened. Ridinger said that he will complete his review business soon and it may lead to disposals and management changes as he forecast lower-than-expected 2013 earnings.
Bloomberg

No comments: